ArticleDrug design, development and therapy2018
Saikosaponin A modulates remodeling of Kv4.2-mediated A-type voltage-gated potassium currents in rat chronic temporal lobe epilepsy.
Article in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- New advances in Traditional Chinese Medicine interventions for epilepsy: where are we and what do we know?Chinese medicine · 2025Review
- Pharmacology, medical uses, and clinical translational challenges of Saikosaponin A: A review.Heliyon · 2024Review
- In Vivo Evaluation of Self-assembled nano-Saikosaponin-a for Epilepsy Treatment.Molecular biotechnology · 2024Article
- Voltage-gated potassium channels and genetic epilepsy.Frontiers in neurology · 2024Review
- Role of Pyroptosis, a Pro-inflammatory Programmed Cell Death, in Epilepsy.Cellular and molecular neurobiology · 2023Review
- A narrative review on traditional Chinese medicine prescriptions and bioactive components in epilepsy treatment.Annals of translational medicine · 2023Review
- Saikosaponin A and Its Epimers Alleviate LPS-Induced Acute Lung Injury in Mice.Molecules (Basel, Switzerland) · 2023Article
- The role of dendritic spines in epileptogenesis.Frontiers in cellular neuroscience · 2023Review
- Identification of key potassium channel genes of temporal lobe epilepsy by bioinformatics analyses and experimental verification.Frontiers in neurology · 2023Article
- Saikosaponin-D Mitigates Oxidation in SH-SY5Y Cells Stimulated by Glutamate Through Activation of Nrf2 Pathway: Involvement of PI3K.Neurotoxicity research · 2022Article
- Analysis of Medication Rule of Primary Epilepsy Based onEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Chinese Herbal Medicine for Treating Epilepsy.Frontiers in neuroscience · 2021Review
- Research Progress on Classical Traditional Chinese Medicine Jieyu Pills in the Treatment of Depression.Neuropsychiatric disease and treatment · 2020Review
- A Model of Chronic Temporal Lobe Epilepsy Presenting Constantly Rhythmic and Robust Spontaneous Seizures, Co-morbidities and Hippocampal Neuropathology.Aging and disease · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic temporal lobe epilepsy (cTLE) is the most common intractable epilepsy. Recent studies have shown that saikosaponin A (SSa) could inhibit epileptiform discharges induced by 4 action potentials and selectively increase the transient inactivating K MATERIALS AND
methodsAll in vitro spontaneous recurrent seizures (SRS) were recorded with continuous video monitoring. Nissl's staining was used to evaluate the SSa protection of neurons and immunohistochemistry, Western blot, and quantitative reverse transcription PCR were used to quantify the expression of Kchip1 and Kv4.2 in the hippocampal CA1 field and the adjacent cortex following Li-pilocarpine induced status epilepticus. We used whole-cell current-clamp recordings to evaluate the anticonvulsant activities of SSa in a hippocampal neuronal culture model of cTLE, while whole-cell voltage-clamp recordings were used to evaluate the modulatory effects of SSa on Kv4.2-mediated
resultsSSa treatment significantly reduced the frequency and duration of SRS over the course of eight weeks and increased the production of Kchip1 and Kv4.2. In addition, SSa attenuated spontaneous recurrent epileptiform discharges (SREDs) in the hippocampal neuronal model and up-regulated Kv4.2-mediated
conclusionsSSa exerted a disease-modifying effect in our cTLE rat model both in vivo and in vitro; the increase in Kv4.2-mediated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.